Welcome to our dedicated page for VVY news (Ticker: VVY), a resource for investors and traders seeking the latest updates and insights on VVY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VVY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VVY's position in the market.
Vivoryon Therapeutics (VVY) reported Q3 2025 results and business updates on December 4, 2025. The company highlighted new pooled analyses from its varoglutamstat Phase 2 program showing a consistent treatment effect on kidney function, with improvements of 5.3–7.7 mL/min/1.73m2/year in lower baseline eGFR percentiles, and presented VIVIAD data at ASN Kidney Week on November 6, 2025.
Corporate updates include a successful private placement raising EUR 5.1 million (3,380,500 shares at EUR 1.50) extending cash runway into Q3 2026, and a CFO transition with Marcus Irsfeld named permanent CFO in December 2025. Financials: R&D expenses down to EUR 3.7m, net loss EUR 7.6m, and cash of EUR 2.5m as of September 30, 2025.
Vivoryon Therapeutics (Euronext: VVY) will publish its Q3 2025 financial results and provide an operational update on December 4, 2025. The company will host a public conference call and live webcast at 3:00 pm CET / 9:00 am EST to discuss results and corporate developments.
Investors can access the live audio webcast on the company's investor site and join the call by pre-registering for phone dial-in details. Attendees are advised to dial in 15 minutes before the scheduled start to avoid delays.
Vivoryon Therapeutics (Euronext: VVY) presented Phase 2 kidney function and biomarker data on November 6, 2025 at ASN Kidney Week 2025. A late-breaking poster titled “Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial” reported that a decrease in pE-CCL2 at week 48 correlated significantly with a positive (improved) eGFR slope on an individual-patient level. Prior VIVIAD Phase 2b results also linked pE-CCL2 reduction with eGFR improvement across dose groups and in participants with and without diabetes. Vivoryon said it plans a dedicated Phase 2b in advanced diabetic kidney disease (DKD stage 3b/4), with initiation subject to additional funding or partnership.
Vivoryon Therapeutics (Euronext: VVY) announced management will participate in multiple medical and investor conferences in November 2025.
Key events: ASN Kidney Week 2025 (Houston, Nov 5–9) where Vivoryon presents a late-breaking poster on eGFR and pE-CCL2 correlation from the Phase 2b VIVIAD trial (TH-PO1206) on Nov 6, 10:00 am–12:00 pm CST; 1x1 meetings around Jefferies Global Healthcare Conference (London, Nov 18–20); and Deutsches Eigenkapitalforum (Frankfurt, Nov 24–26).
Attending speakers include Michael Schaeffer, PhD, Frank Weber, MD, and Julia Neugebauer, PhD. Investor meeting requests via IR@vivoryon.com.
Vivoryon Therapeutics (Euronext: VVY) completed a private placement on October 6, 2025, raising EUR 5.1 million by issuing 3,380,500 new ordinary shares at EUR 1.50 per share.
The placement equals 12.9% dilution of existing share capital, raises shares outstanding to 29,614,337, and increases share capital from EUR 262,338.37 to EUR 296,143.37.
Proceeds will fund near-term development of lead candidate varoglutamstat in diabetic kidney disease, support partnership negotiations, and provide a cash runway well into Q3 2026. New shares are expected to trade on Euronext Amsterdam on October 7, 2025 with delivery around October 9, 2025.
Vivoryon Therapeutics N.V. (VVY) reported H1 2025 financial results and significant progress in their kidney disease program. Key highlights include compelling kidney function data from two Phase 2 studies (VIVIAD and VIVA-MIND), showing varoglutamstat's ability to improve eGFR values. The company secured a new U.S. patent for varoglutamstat extending protection through 2044.
Financial results show a reduced net loss of EUR 5.5M compared to EUR 13.6M in H1 2024, with R&D expenses decreasing to EUR 2.8M from EUR 10.3M. Cash position stands at EUR 4.8M, expected to fund operations into January 2026. The company entered a EUR 15M Standby Equity Purchase Agreement with Yorkville Advisors and is actively seeking additional funding for planned Phase 2b DKD studies.
Pre-clinical data revealed synergistic effects when combining varoglutamstat with SGLT-2 inhibitors, showing promising results in inflammation, fibrosis, and kidney function markers.Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases, has scheduled its H1 2025 financial results announcement for September 4, 2025.
The company will host a conference call and webcast at 3:00 pm CEST / 9:00 am EDT. The financial report will be accessible on Vivoryon's website, and participants can join via phone by pre-registering through the provided link or attend via live audio webcast.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases, has announced its upcoming participation in two virtual investor conferences.
Management will present at the mwb online Health Care Conference on July 1, 2025, at 12:00 pm CEST, and the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 3:00 pm CEST / 9:00 am EDT. CEO Frank Weber and COO Julia Neugebauer will represent the company at both events.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly diabetic kidney disease, held its 2025 Annual General Meeting (AGM) on June 24, 2025.
Shareholders approved all agenda items, including the appointment of Dr. Julia Neugebauer (COO since May 2025) as executive director. The meeting also confirmed the re-appointment of executive directors Dr. Frank Weber and Anne Doering, along with non-executive directors Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl, and Dr. Samir Shah.